A clinical trial platform to rapidly test drugs and diagnostics to fight COVID-19

TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, launched Project CoValence, an initiative that will enable public and private researchers to test emerging drugs and diagnostics for COVID-19.


For researchers, Project CoValence provides the technology infrastructure, clinical operations, and logistical support needed to run COVID-19 clinical trials. The platform is optimized for outpatient or community-based studies centered at the patient home, reducing the burden for hospitals and health systems. Academic and industry researchers with ideas that they want to test can leverage this shared infrastructure to rapidly launch their trials. In particular, the project aims to support trials requiring unique recruitment strategies, remote data collection, telemedicine, and other capabilities that are challenging during the pandemic.

Project CoValence is a collaborative partnership between TrialSpark, Sam Altman, CEO of OpenAI, and Dr. Mark C. Fishman, Harvard professor and Founding President of the Novartis Institutes for Biomedical Research.

Get in Touch

For any details or inquiries, reach out at contact@openresearchlab.org.


You have successfully subscribed to our newsletter